載入...
Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations
BACKGROUND: Epidermal growth factor receptor (EGFR) is one of the most common oncogenes in non-small cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitor (TKI) and platinum-doublet chemotherapy (PT) are effective regimens in patients with NSCLC harbouring EGFR mutations. Among these patients, pr...
Na minha lista:
| 發表在: | ESMO Open |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMJ Publishing Group
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6267457/ https://ncbi.nlm.nih.gov/pubmed/30559979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000399 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|